Clinical pharmacology of N,N-bis(phenylcarbamolymethyl)dimethylammonium chloride (QX-572), a new antiarrhythmic agent.
D000328:Adult; D000368:Aged; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001219:Aspartate Aminotransferases / Q000097:blood; D001772:Blood Cell Count; D001783:Blood Flow Velocity; D001786:Blood Glucose / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004285:Dogs; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D014508:Urea / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D001786:Blood Glucose; D004071:Digitalis Glycosides; D000644:Quaternary Ammonium Compounds; D014508:Urea; D001219:Aspartate Aminotransferases; D011342:Procainamide